Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMS5552 and Metformin DDI in T2DM
NCT02597400Phase 1Completed
- Sponsor
- Hua Medicine
- Start
- Oct 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dorzagliatin in type 2 diabetes mellitus (T2DM), sponsored by Hua Medicine. Primary endpoint: Maximum Plasma Concentration at 13 days. Started Oct 2015; status: completed.
02
Drugs
dorzagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02597400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02597400.